Vivos Therapeutics gains Nevada insurance coverage, cuts costs

Vivos Therapeutics Inc. (NASDAQ: VVOS) announced that physician-owned professional practices supported by its management services subsidiary in Nevada have received in-network status with multiple commercial health insurers and participating status with Medicare.

The covered insurers include Medicare, TRICARE, UnitedHealthcare, UMR, Intermountain Health, Select Health, CareSource, Anthem, Aetna, Cigna, Health Plan of Nevada, Humana, Molina, and Wellcare. These payers collectively cover a substantial portion of the insured population in the Las Vegas metropolitan area.

The Colorado-based medical device company develops treatments for obstructive sleep apnea using its Complete Airway Repositioning and Expansion devices, which have FDA 510(k) clearance for treating severe OSA in adults and moderate to severe OSA in children ages 6 to 17.

"Previously, many OSA patients who were excited about Vivos treatment as an alternative to CPAP were denied coverage by their insurance company or Medicare," said CEO Kirk Huntsman. The company stated that supported practices have thousands of previously evaluated patients who can now be contacted regarding insurance coverage availability.

Separately, Vivos implemented cost reduction initiatives beginning in February 2026, including workforce reductions and vendor relationship changes related to its legacy dental-focused distribution model. The company estimates these measures will result in approximately $4 million in annual expense savings based on annualized calculations, though actual savings may vary.

The company expects the combination of increased revenue from in-network status and cost reductions to reduce its cash burn rate and advance its goal of achieving positive cash flow during fiscal year 2026.

You May Also Be Interested In

• Zeta Surgical begins TMS navigation treatments at Hope Therapeutics clinics
• Vishay Intertechnology Automotive Grade Ambient Light Sensors Deliver Accurate Visible Light Measurement with no IR Bump
• Pelican Way Research shorts Hyliion Holdings (HYLN) on VFG deal concerns